Clinical Trial Search

Primary: Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours) — 6.92; 6.51 log-transformed total cough count

Primary: Consumption of Fentanyl — 41; 50; 58 mg

Primary: Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment — 80.9; 78.2; 81.0; 61.5 Percentage of participants

Primary: Percentages of Participants With Local Reactions By Severity Within 14 Days of Any Vaccination — 50.0; 9.5; 30.0; 15.0 Percentage of participants

Primary: Proportion of Patients Remaining in Study at 1 Year — 0.265; 0.315 proportion of participants — p=0.57

Primary: Number of Participants Reporting One or More Adverse Drug Reactions (ADR) — 230 Participants

Primary: Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12…

Primary: The Berg Balance Scale (BBS) — -0.06; 4.1; 0.8; 2.3 units on a scale — p=0.001

Primary: Adjusted Annualized Relapse Rate Between Baseline and Week 52 — 0.458; 0.211; 0.230 relapses per person-years — p=<0.0001

Primary: Incidence and Severity of Ocular Adverse Events — 0 number of adverse events

Primary: Visual Analog Scale (VAS) for Pain — 6; 4; 4 units on a scale

Primary: KOOS - Pain — 17.6; 9.1 units on a scale — p=0.181

Primary: Length of Stay — 287 minutes

Primary: Percentage of Participants Achieving a Response in Systemic Lupus Erythematosus Responder Index 4 (SRI [4]) — 45.4; 58.3; 56.5; 59.8 percentage of participants — p=0.057

Primary: Area Under the Concentration Versus Time Curve (AUClast) — 686.98; 1247.63; 1769.58 h*pg/mL